| Purpose | (Clinical Focus: This value set serves as a comprehensive reference for medications used in masculinizing hormone therapy (MHT) for transgender men. It combines two key components:),(Data Element Scope: This value set provides a standardized approach to documenting all medication components of a typical MHT regimen for transgender men. It encompasses both injectable and transdermal administration routes used to deliver testosterone, the primary hormone for masculinization.),(Inclusion Criteria: The value set references two underlying child value sets:
"Transmasculine Regimens, Testosterone, Parenteral": captures a comprehensive range of injectable testosterone products.
"Transmasculine Regimens, Testosterone, Transdermal": includes various transdermal delivery methods for testosterone.),(Exclusion Criteria: This value set relies on the underlying child value sets for specific details on testosterone medications, formulations, and dosages.
It does not capture information about the specific sequence or combination of testosterone products used in a particular MHT regimen.
It excludes other medications that may be part of transgender healthcare, such as medications for specific health conditions or medications used to address other aspects of gender presentation (e.g., finasteride).) |
FHIR